NRX Pharmaceuticals, Inc. (NRXP) · Oct 16, 2026 · Other events
Annual meeting scheduled — December 17, 2026 meeting; October 25 proposal and nomination deadline
NRx Pharmaceuticals scheduled its 2026 annual meeting for December 17 and reset proposal and director-nomination deadlines, but disclosed no business update.
NRx is a clinical-stage biopharmaceutical company advancing preservative-free ketamine products and NRX-101 toward FDA approval while building related clinic operations. This filing is governance housekeeping, not a change to that operating story. It sets the 2026 annual meeting for December 17, 2026, in a virtual-only format.
The only potentially consequential element is the shortened window for shareholder action. Because the meeting is being held more than 30 days before the anniversary of the March 23, 2026 annual meeting, prior proposal and nomination deadlines no longer apply; the new deadline is October 25, 2026, with Rule 14a-19 proxy-solicitation notice due October 26. 〔0〕 No shareholder proposal, activist slate, or contested matter is disclosed here, so the reset itself should not be read as evidence of one.
Bottom line: This is a procedural annual-meeting notice with no disclosed impact on NRx’s drug-development or commercialization plans. It matters mainly because it opens a defined, near-term window for shareholder proposals or director nominations—not because the filing changes the business.
2026 annual meeting, December 17, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!